Key Points from Biosense Webster’s CE Mark Approval for VARIPULSE Platform
- Biosense Webster has obtained CE mark approval for the VARIPULSE Platform, a cutting-edge system for treating atrial fibrillation that integrates PFA technology with real-time 3D mapping.
- The inspIRE trial highlighted the platform’s effectiveness, with 80% of patients achieving freedom from recurrence, offering enhanced treatment options for patients with atrial fibrillation.
- Expert Tom De Potter praises the CE mark approval of the VARIPULSE Platform as a game-changer in catheter ablation technology, emphasizing the platform’s significant leap forward in patient care for atrial fibrillation.